[Remote] AI Research Engineer at Abata Therapeutics

London, England, United Kingdom

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Healthcare, Drug DiscoveryIndustries

Requirements

Bachelor's degree in Computer Science, Engineering, or related fields
Minimum of two years of industry experience in AI, machine learning, or related roles, with a track record of successfully implementing and deploying AI models in production environments
Proficiency in programming languages such as Python, and experience with relevant libraries, toolchain and frameworks for AI model development
Strong understanding of deep learning fundamentals, including neural network architectures, optimization techniques, and evaluation metrics
Familiarity with drug discovery processes, computational chemistry, or bioinformatics is desirable
Excellent problem-solving skills, with a keen eye for detail and a passion for tackling complex challenges in healthcare
Effective communication and collaboration abilities, with the capacity to work effectively in a fast-paced, multidisciplinary team environment
Experience solving complex problems and comparing alternative solutions, tradeoffs, and diverse points of view to determine a path forward
Experience working and communicating cross-functionally on an interdisciplinary team
Publication track record at conferences such as NeurIPS, ICML, ICLR, etc

Responsibilities

Collaborate closely with AI scientists, engineers, and drug discovery experts
Help develop AI models to accelerate the identification and development of novel therapeutics

Skills

Python

Machine Learning

Deep Learning

Model Deployment

Production AI

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free